The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 07, 2021

Filed:

Feb. 14, 2020
Applicant:

Ksq Therapeutics, Inc., Cambridge, MA (US);

Inventors:

Micah Benson, Cambridge, MA (US);

Jason Merkin, Cambridge, MA (US);

Gregory V. Kryukov, Cambridge, MA (US);

Solomon Martin Shenker, Cambridge, MA (US);

Michael Schlabach, Cambridge, MA (US);

Noah Tubo, Cambridge, MA (US);

Assignee:

KSQ Therapeutics, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); C12N 15/113 (2010.01); A61K 35/17 (2015.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/32 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); A61P 35/04 (2006.01); A61P 35/02 (2006.01); A61P 35/00 (2006.01); C12N 9/22 (2006.01); A61K 38/00 (2006.01); A61K 35/12 (2015.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/11 (2013.01); A61K 35/17 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61P 35/04 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 16/2803 (2013.01); C07K 16/2863 (2013.01); C07K 16/32 (2013.01); C12N 5/0636 (2013.01); C12N 9/22 (2013.01); C12N 15/113 (2013.01); C12N 15/1138 (2013.01); A61K 38/00 (2013.01); A61K 2035/124 (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C12N 2310/122 (2013.01); C12N 2310/14 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01);
Abstract

The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.


Find Patent Forward Citations

Loading…